CETP INHIBITORS AND METABOLITES THEREOF

摘要

Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholesteryl ester transfer protein (CET P) inhibitors, pharmaceutical compositions containing such inhibitors and the usi-, of such inhibitors to elevate cert in plasma lipid levels, including high den~;ity lipoprotein (HDL)-cholesterol and t lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-chole terol and triglycerides.